Apposite Capital-backed 1Med acquires French CRO, Evamed

Apposite Capital-backed 1MED, a specialist Contract Research Organisation (“CRO”) providing regulatory and clinical support to medical device companies, has announced that it has acquired Evamed, a CRO based in northwest France also focused on the medical device market.

Created in 2005, Evamed has strong expertise in clinical study global management for all types of medical device (from class I to class III) and for all therapeutic fields with most projects concentrated on higher risk devices. Evamed helps manufacturers with complex studies to support efficient regulatory approval and rapid access to market.

This acquisition establishes 1MED’s presence in France, a key European market, and further strengthens the company’s capabilities in clinical trials, including further high complexity interventional trials with higher risk devices.

Evamed’s customers will benefit from having access to a larger platform and a wider network of partners as well as 1MED’s high quality specialist regulatory services.

The acquisition is an important step that reinforces 1MED’s positioning as a pan-European boutique medical device CRO.

PMSI provided the CDD for the deal including in-depth research into the impact of MDR and its recent deadline extensions on medical device manufacturers, the state of current compliance in the French market, as well as an analysis of Evamed’s competitive positioning.

1MED acquires French CRO, Evamed